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Abstract Autoantibodies directed against specific human ami-
noacyl-tRNA synthetases have been associated with a clinical
picture including myositis, arthritis, interstitial lung disease and
other features that has been referred to as the ‘anti-synthetase
syndrome’. Anti-asparaginyl-tRNA synthetase autoantibodies
(anti-KS), the most recently described anti-synthetase autoanti-
bodies, are directed against human cytosolic asparaginyl-tRNA
synthetase and neutralize specifically its activity. Here we show
that these antibodies recognize two epitopes on the human
enzyme, an N-terminal epitope reactive in immunoblot experi-
ments and a heat-labile epitope in the catalytic domain. In
contrast to the well studied anti-Jo-1 autoantibodies anti-KS
when bound to the synthetase increase the affinity of the
synthetase for its tRNA substrate and prevent aminoacylation
without interfering with the amino acid activation step. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Aminoacyl-tRNA synthetases (aaRSs) are key components
of the protein translation machinery that catalyze a two-step
reaction leading to correct aminoacylation of isoacceptor
tRNA. The 20 aaRSs present in most prokaryotic and eukary-
otic species can be divided into two classes of 10 members
each, distinguished by their catalytic domain topology [1,2].
A subset of the human autoimmune diseases, the idiopathic
in£ammatory myopathies, are characterized by the existence
of high a⁄nity neutralizing anti-cytoplasmic tRNA synthetase
antibodies. To date, six di¡erent anti-synthetase antibodies
have been described and each one inhibits a speci¢c cytosolic
aaRS ^ anti-PL12 (AlaRS), anti-PL7 (ThrRS), anti-OJ
(IleRS), anti-Jo-1 (HisRS), anti-EJ (GlyRS), and anti-KS
(AsnRS) [3].
The mechanism by which the six known anti-synthetase
autoantibodies block aminoacylation is not fully understood.
It is known, however, that some anti-synthetase antibodies
can directly precipitate tRNA independent of the correspond-
ing aaRS. However, other anti-synthetase antibodies, such as
anti-asparaginyl-tRNA synthetase autoantibodies (anti-KS),
react only with the enzyme:tRNA complex. Thus the mecha-
nisms underlying aminoacylation inhibition are likely to be
di¡erent among the di¡erent anti-synthetase antibodies. One
hypothesis for the inhibitory e¡ect of anti-synthetase antibod-
ies on aaRS is that autoantibody might disrupt protein fold-
ing and/or conformational changes associated with substrate
binding. Therefore, to understand the mechanism by which
anti-KS inhibit aminoacylation, we examined the interaction
of anti-KS on recombinant wild-type human cytosolic AsnRS
(HsAsnRSc) and a series of HsAsnRSc deletion mutants cor-
responding to various enzyme domains. The speci¢city of
anti-KS was compared to other known anti-synthetase anti-
bodies, and the e¡ect of anti-KS on HsAsnRSc was measured
on the amino acid activation step and on the overall reaction.
2. Materials and methods
2.1. Autoimmune sera
Anti-KS sera were obtained from six di¡erent Japanese subjects
(KS-prototype and KS1^KS5) for comparative immunological stud-
ies. Patients exhibiting rheumatological disease, characterized by a
combination of in£ammatory myositis with or without arthritis and
interstitial lung disease, were screened for the presence of autoanti-
body as described previously by Hirakata and coworkers [4]. Control
sera were collected from healthy normal subjects.
2.2. Construction of deletion mutants
HsAsnRSc mutants were constructed by site-directed mutagenesis
(QuickChange1 Site-Directed Mutagenesis Kit, Stratagene) using
polymerase chain reaction (PCR) and the plasmid containing wild-
type HsAsnRSc cDNA as template. All cDNA sequences were cloned
back into the pCal-n vector between the BamHI and EcoRI restriction
sites. Complementary anti-parallel primers (listed below) were ex-
tended during temperature cycling using Pfu DNA polymerase. Prim-
ers for AsnRS1ÿ221 (1) introduce two stop codons, primers for
AsnRS108ÿ548 (2) a BamHI restriction site. Mutated nucleotides are
in bold:
1. 5P-GACAACCTGATCAATTAGTAGTCTGACGTTGATGTCC-
AGC-3P
2. 5P-GATTACCATTAAA AAGGATCCAGTCTCCCAGAGCCA-
AAATGTGTG-3P
A BamHI digestion for the AsnRS108ÿ548 construct eliminated a Bam-
HI^BamHI fragment in order to obtain the ¢nal mutant constructs in
phase with the calmodulin tag.
2.3. Expression and puri¢cation of recombinant
asparaginyl-tRNA synthetases
The cDNA encoding human cytosolic AsnRS was ampli¢ed by
PCR using a human liver 5P RACE-Ready cDNA library from Clon-
tech as template. Suitable primers were designed using EST sequence
information of human ESTs encoding peptides showing high sequence
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similarities with yeast AsnRS. The complete cDNA was cloned into
the pCal-n expression vector [5]. BL21(DE3) pCal-n HsAsnRSc cells
expressing the human enzyme were grown in LB-ampicillin at 37‡C to
an optical density of 0.6 at 600 nm. Isopropyl-L-D-thiogalactopyrano-
side (IPTG) was added to a ¢nal concentration of 0.2 mM and in-
cubation continued for 6 h at 23‡C. Cells were then lysed by sonica-
tion. The bacterial extract was applied to a calmodulin a⁄nity column
for puri¢cation. The CBP tag was removed by proteolytic digestion
with thrombin. Brugia malayi AsnRS [6] was puri¢ed similarly from
an overproducing pCal-n clone. Puri¢ed yeast aspartyl-tRNA syn-
thase (AspRS) was obtained from Dr. Gilbert Eriani, IBMC, Stras-
bourg, France.
2.4. Immunoassays using autoimmune (anti-KS) serum
The immunological reactivity of recombinant proteins was tested in
two ways. For Western blot analysis, puri¢ed protein samples (wild-
type and mutant AsnRS) were separated electrophoretically on a 12%
SDS polyacrylamide gel and transferred to an Immobilon-P mem-
brane [7]. Detection of bound protein was visualized using 5.0 Wl of
human anti-KS-type serum as a primary antibody. Anti-human IgG
peroxidase conjugate with the SuperSignal0 chemiluminescent sub-
strate (Pierce) was used for detection of anti-KS.
ELISA plates were coated in duplicate with 1 Wg of human re-
combinant antigen by overnight incubation at 4‡C and were assayed
as described elsewhere using mouse anti-human IgG conjugated to
peroxidase [8].
2.5. Aminoacylation and neutralization assays
Aminoacylation assays measure incorporation of [14C]Asn as pre-
viously described using unfractionated yeast tRNA and 2 WM puri¢ed
HsAsnRSc [9].
Antibody-mediated neutralization assays using puri¢ed wild-type
and mutant HsAsnRSc, B. malayi and Thermus thermophilus AsnRS
[10] or suitable dilutions of bacterial extracts containing overexpressed
yeast AsnRS [11] were performed as described elsewhere [5] using
unfractionated tRNA.
2.6. Gel retardation assays
Gel retardation experiments were performed to examine the e¡ect
of anti-KS on tRNA binding to AsnRS. Yeast tRNAAsn was tran-
scribed in vitro using [K-32P]UTP. Labeled tRNA was puri¢ed by
electrophoresis on an 8% polyacrylamide 8 M urea gel followed by
overnight elution in 0.3 M sodium acetate (pH 7) and ethanol pre-
cipitated. The samples were redissolved in water to obtain 200 000
cpm/Wl and renatured by heating for 3 min at 95‡C and cooling for
5 min at 4‡C. Renaturation bu¡er containing 10 mM Tris^HCl pH 8
and 10 mM MgCl2, and 10 mM KCl was added. For each test,
200 000 cpm of 32P-radiolabeled yeast tRNA was incubated with
2 WM of recombinant protein for 5 min on ice in a total volume of
10 Wl containing 25 mM HEPES bu¡er pH 7, 75 mM KCl, 10 mM
MgCl2, and 25% glycerol, and loaded on a native 6% (19:1) acrylam-
ide^bisacrylamide gel. The electrophoresis was carried out in running
bu¡er (50 mM sodium acetate and 110 mM magnesium acetate) at
4‡C for 45 min. For experiments involving anti-KS, the protein was
preincubated with 5 Wl of serum (1:5 to 1:5000 dilution) on ice for
5 min.
2.7. ATP^PPi exchange reaction
An activity test was performed in the presence or absence of anti-
KS serum using an ATP^32PPi exchange reaction to verify if the ¢rst
step of the aminoacylation reaction is inhibited by autoimmune se-
rum. Since the ¢rst step of the aminoacylation reaction is reversible,
i.e. ATP-mediated formation of asparagine adenylate, formation of
radioactive ATP can be measured by providing 32PPi to a reaction
mixture containing HsAsnRSc (2 WM) and asparagine [12].
2.8. Competition of mutant HsAsnRScs for anti-KS
The ability of various domains of HsAsnRSc to bind autoantibody
was examined in competition tests. Both mutant proteins,
AsnRS108ÿ548 (0^650 pmol) and AsnRS1ÿ221 (0^1780 pmol), which
are devoid of aminoacylation activity, were tested for their capacity
to compete with the wild-type enzyme (40 pmol) for the binding of
neutralizing antibodies in order to localize the region of the human
AsnRS responsible for aminoacylation inhibition. Evidence of com-
petition exists if the wild-type enzyme regains its activity via the re-
moval of neutralizing antibodies by the mutant proteins. Competitor
protein was preincubated with anti-KS and control serum. After in-
cubation, sera were used in aminoacylation inhibition assays as de-
scribed above.
3. Results
3.1. Anti-KS sera speci¢cally interact with human AsnRS
As previously described for the anti-KS prototype serum
[5], ¢ve other anti-KS sera were tested for their neutralizing
activity and reactivity in ELISA tests. All six anti-KS sera
inhibited the aminoacylation reaction of HsAsnRSc. The in-
hibition level was reproducible with an average inhibition of
80%. Two others anti-synthetase sera tested, anti-AlaRS (anti-
PL12) and anti-HisRS (anti-Jo-1), did not neutralize the hu-
man AsnRS activity. Also, polyclonal rabbit serum raised
against the human protein did not inhibit human AsnRSc
aminoacylation activity, suggesting that epitopes recognized
by the rabbit serum are di¡erent from those recognized by
anti-KS. In ELISA tests 50% of maximal reactivity was mea-
sured at KS serum dilutions of 1:5000 to 1:50 000. To inves-
tigate the speci¢city of the anti-KS sera, we used yeast AspRS
as antigen in ELISA tests. AspRS belongs to the same sub-
class of synthetases (IIb) as AsnRS and both enzymes show
signi¢cant sequence similarities. No immunoreactivity with
anti-KS sera was observed. Furthermore, AsnRS from bacte-
rial (T. thermophilus) or nematode (B. malayi) origin did not
react with anti-KS sera. This demonstrates the high speci¢city
of the KS autoantibodies.
3.2. Localization of epitopes
To localize the epitopes recognized by anti-KS sera, dele-
tion mutants of the human synthetase were constructed by
site-directed mutagenesis (Fig. 1A): AsnRS108ÿ548 lacking
the ¢rst 107 amino acids (N-terminal eukaryote-speci¢c do-
main) and AsnRS1ÿ221 corresponding to the ¢rst 221 amino
Fig. 1. Epitope localization. A: Schematic organization of
HsAsnRSc according to the structural data from the thermophilic
AsnRS enzyme [19]. Deletion mutants of the HsAsnRSc are desig-
nated by lines. B: Autoradiography of the Western blot showing
the reactivity of two AsnRS mutants with anti-KS prototype serum.
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acids (N-terminal eukaryote-speci¢c domain and the L-barrel
domain) of the human protein. Each mutant protein was ex-
pressed, puri¢ed and analyzed for its immunoreactivity in
Western blot experiments, ELISA and a competition assay.
For both mutant proteins, the L-barrel domain is required to
obtain stability and proper folding.
Fig. 1B shows that the antibodies present in anti-KS serum
speci¢cally interact with the wild-type AsnRS, and the mutant
protein corresponding to the N-terminal and the L-barrel do-
main of the protein (AsnRS1ÿ221). The mutant protein corre-
sponding to the catalytic domain with the L-barrel domain of
the protein (AsnRS108ÿ548) is not reactive in Western blots.
The immunoreactivity of the human protein in Western blot
experiments seems to be due to the reactivity of its N-terminal
domain suggesting the presence of a linear epitope or an epi-
tope with the capacity to refold on membrane in this region
(residues 1^221). ELISA tests with anti-KS-type sera using
AsnRS1ÿ221 and AsnRS108ÿ548 mutants in equimolar quanti-
ties as antigen show approximately a threefold higher reactiv-
ity with the catalytic domain mutant protein. These results
suggest the presence of the immunodominant epitope in the
catalytic domain of HsAsnRSc. To study the heat stability of
the epitope(s), we preincubated wild-type enzyme, AsnRS1ÿ221
and AsnRS108ÿ548 at di¡erent temperatures and measured the
residual ELISA reactivity with KS serum. Wild-type and the
catalytic L-barrel domain mutant AsnRS108ÿ548 lost 50% reac-
tivity after preincubation at 50‡C. The N-terminal L-barrel
mutant showed a stronger structural stability for its epitopes.
Loss of 50% of immunoreactivity was observed for a temper-
ature close to 65‡C. This observation might explain the reac-
tivity of the N-terminal epitope in Western blot experiments.
The mutant proteins AsnRS1ÿ221 and AsnRS108ÿ548 are de-
void of aminoacylation activity. The correct folding of
AsnRS108ÿ548 was tested by the ATP^PPi exchange reaction
(data not shown) monitoring the ¢rst step of the aminoacyla-
tion reaction which requires a correct structural organization
of the catalytic domain.
In competition tests, the mutant protein AsnRS108ÿ548 in-
teracts with the neutralizing antibody allowing the wild-type
enzyme in the presence of KS serum to recover its initial
activity (Fig. 2). In contrast, the neutralizing antibodies do
not recognize the mutant protein AsnRS1ÿ221 which is inactive
in the competition test. The absence of immunoreactivity of
AsnRS108ÿ548 in Western blot analysis using anti-KS sera,
together with its capacity to prevent neutralization by anti-
KS serum, suggests that the neutralizing epitope is conforma-
tional and localized in the catalytic domain of the human
enzyme.
3.3. Autoantibody alters the a⁄nity of HsAsnRSc for tRNA
Analysis of the ¢rst step of the reaction (amino acid acti-
vation) by ATP^PPi exchange showed that there is no signi¢-
cant di¡erence in radioactive ATP formation in the absence or
presence of the anti-KS serum, indicating that antibody bind-
ing does not interfere with the amino acid activation step
(data not shown). Therefore we studied the e¡ect of the auto-
immune serum on the a⁄nity of the synthetase for its macro-
molecular substrate tRNA.
Gel retardation experiments demonstrated that KS antibod-
ies do not recognize free tRNA (Fig. 3A, lane 3). Under non-
saturating concentrations of synthetase (Fig. 3A, lanes 4 and
5) free tRNA and complexed tRNA can be observed. Two
Fig. 2. Localization of the neutralizing autoepitope. Increasing con-
centrations of the competitor protein AsnRS108ÿ548 were added to
wild-type HsAsnRSc (0.8 WM) in the presence of neutralizing KS
autoantibody (1:10 dilution). The mutant protein AsnRS108ÿ548 is
not active in the aminoacylation reaction.
Fig. 3. In£uence of KS serum on the a⁄nity of HsAsnRSc for its
tRNA substrate. A: Autoradiogram of a gel retardation experiment
obtained with [K-32P]UTP yeast tRNA. Radiolabeled tRNA is
present in each lane. CS corresponds to control serum and KS to
KS serum. Serum dilutions used are indicated. B, C: Autoradio-
grams of quantitative gel retardation experiments obtained with
yeast tRNAAsn complexed to native HsAsnRSc in the absence (B) or
presence (C) of KS autoantibody. Radiolabeled tRNA is present in
each lane. Increasing concentrations of HsAsnRSc were used.
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forms of complexed tRNA (*) exist, most likely corresponding
to one molecule of tRNA/dimer and two molecules of tRNAs/
dimer of AsnRS. Control serum did not modify the pattern of
free and complexed tRNA (Fig. 3A, lane 6). However, with
the anti-KS serum (Fig. 3A, lane 7) the pattern is totally
changed. No more free tRNA can be observed. A new band
with a slightly slower migration compared to the complexed
tRNA in the absence of KS appears, corresponding to a
supercomplex composed of synthetase, tRNA and antibody.
Anti-KS does not prevent the tRNA binding. When the anti-
body concentration decreases, the pattern corresponding to
the synthetase^tRNA complex and free tRNA progressively
reappears. According to the pattern obtained in the presence
of anti-KS serum (Fig. 3A, lane 7), it seems that the antibody
has a stabilizing e¡ect on the tRNA^protein complex.
This e¡ect was studied in more detail by gel retardation
experiments in the absence (Fig. 3B) or presence (Fig. 3C)
of anti-KS serum. Due to the shorter migration only the sep-
aration in uncomplexed or complexed tRNA is visible. In the
absence of anti-KS, the shift corresponding to the tRNA^
synthetase complex formation is obtained with a minimal con-
centration of 0.6 WM of human protein. When the KS serum
is added (1:200 ¢nal dilution) this shift appears at about ¢ve
times lower protein concentrations (60^125 nM). Therefore,
the anti-synthetase serum with neutralizing activity increases
the a⁄nity of the synthetase for its substrate tRNA.
4. Discussion
Anti-KS represents the sixth in a series of human autoanti-
bodies recognizing aminoacyl-tRNA synthetases. All such
autoantibodies occur in persons with a variant of idiopathic
in£ammatory myopathies, characterized by immune-mediated
lung and/or joint disease [3]. For unknown reasons, rarely
does more than one anti-synthetase antibody occur in the
same patient.
The results of our investigations with recombinant human
AsnRS answer some questions underlying the inhibitory
mechanisms of anti-KS. ATP^PPi exchange reactions showed
no signi¢cant di¡erence in radioactive ATP formation in the
absence or presence of the anti-KS serum, indicating that
antibody binding does not interfere with the amino acid acti-
vation step. Anti-KS, but not normal sera, leads to a higher
a⁄nity of the tRNA for the protein. The neutralizing autoe-
pitope has been localized to the C-terminal part of human
asparaginyl-tRNA synthetase based on binding studies with
deletion derivatives. The tRNA a⁄nity-increasing activity of
the autoantibody was only observed with the entire enzyme.
Therefore we cannot exclude the possibility that both activ-
ities involve di¡erent epitopes. If both activities involve the
same epitope the increased a⁄nity for tRNA might lead to
aminoacylation inhibition by blocking the dissociation of the
tRNA from its synthetase. Alternatively the autoantibody
might induce a conformational change on the synthetase
which interferes with the transfer of the activated amino
acid to the acceptor stem of the tRNA. The heat-labile neu-
tralizing epitope(s) recognized by anti-KS sera requires both
the catalytic and L-barrel domains to adopt suitable structural
conformations.
The N-terminal part of the human AsnRS, similar to the
human HisRS, reactive with Jo-1, contains predicted helix
structures [13]. The immunodominant epitope for Jo-1 is re-
portedly a coiled-coil structure localized in the ¢rst 60 amino
acid of the human HisRS N-terminus. Jo-1 competes with the
small substrates, ATP and histidine [14]. However, in contrast
to that human HisRS/Jo-1 data, our results with AsnRS/anti-
KS show three di¡erences. First, anti-KS-type sera do react in
an immunoblot experiments with residues 1^221 of the AsnRS
N-terminus, but these epitopes are not involved in inhibition.
This is not to say that the two N-terminal regions are totally
distinct. Short regions of sequence similarity do exist in the N-
terminal domains of many eukaryotic AsnRSs from di¡erent
species. For example, a tRNA binding motif has been re-
ported in the N-terminus of yeast aspartyl-tRNA synthetase
and other eukaryotic class IIb aaRSs [15]. Secondly, anti-KS
does not interfere with ATP and asparagine binding. Thirdly,
HisRS inhibition by Jo-1 decreases with increasing phyloge-
netic distance from human. This was demonstrated by show-
ing diminished inhibitory activity of Jo-1 using HisRSs iso-
lated from distant prokaryotic and eukaryotic species [16]. In
contrast, anti-KS does not signi¢cantly inhibit bacterial, yeast
or nematode AsnRSs under the conditions tested. In the past,
it has been suspected that anti-synthetase antibodies that do
not precipitate tRNA alone might interfere with tRNA bind-
ing to aaRSs; however, to our knowledge, anti-KS is the ¢rst
anti-synthetase antibody which has been shown to actually
increase tRNA a⁄nity.
Coiled-coil structures are frequently found in autoantigens
and in other proteins and the concept of molecular mimicry
has often been involved to explain the generation of autoanti-
bodies [17]. The capacity of coiled-coils to bind to nucleic
acids has been demonstrated and many intracellular autoan-
tigens are nucleic acid-binding proteins. Binding of tRNA to
synthetases may be an important factor leading to the devel-
opment of these autoantibodies. Nucleic acid binding is a
feature of several autoantigens in systemic autoimmune dis-
ease [18].
Ultimately, comparison of the three-dimensional atomic
structures of eukaryotic AsnRS and aaRS:autoantibody com-
plexes may help to de¢ne the basis for anti-synthetase anti-
body-mediated inhibition of aaRSs. These endeavors may
prove technically challenging, given the £exibility of amino-
terminal domains in eukaryotic aaRSs. The T. thermophilus
AsnRS revealed that the motif 3 region of the catalytic do-
main interacts with a hinge region linking the N-terminal
anticodon-binding domain to the catalytic core [19]. If this
relationship also holds true for the human enzyme, anti-KS
may interact with a conformation which includes the hinge
region.
Our data do not directly address the underlying pathophys-
iological processes associated with the generation of anti-syn-
thetase antibody in human autoimmune disease. These mech-
anisms are likely to be complex and may require in vivo
con¢rmation of a hypothesis. Molecular mimicry between hu-
man and non-self antigens (e.g. pathogenic microbes) is often
suggested as a mechanism for induction of autoimmunity. But
this theory may be too simplistic to explain the etiology of
anti-synthetase antibodies given the recent evidence from mur-
ine models of autoimmunity. Overexpression of the human
MHCI complex in transgenic mice resulted in production of
neutralizing Jo-1 antibody [20]. Therefore a complete under-
standing of mechanisms involved in the production of auto-
immune phenomena may require detailed structure^function
analysis across protein and non-protein families.
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